Healthcare major Takeda Pharmaceutical (NYSE:TAK) is acquiring clinical-stage company Nimbus Therapeutics’ subsidiary Nimbus Lakshmi and its product candidate NDI-034858.
The drug candidate is an oral, selective tyrosine kinase 2 (TYK2) inhibitor currently being evaluated for multiple autoimmune diseases post a successful Phase2b study in Psoriasis.
Importantly, Nimbus will receive $4 billion in an upfront cash payment and stands to receive a further $2 billion in commercial milestone payments under the deal.
The transaction is anticipated to be finalized in H1 2023. Takeda shares have now climbed 11% over the past month alone.
Read full Disclosure
